Robert J.  Trenschel net worth and biography

Robert Trenschel Biography and Net Worth

Director of Palisade Bio
Dr. Trenschel, who currently serves as the president and chief executive officer of the Yuma Regional Medical Center, has nearly 20 years of healthcare and medical management experience. As a seasoned healthcare executive, he employs patient-centric, physician-focused leadership that harmonizes clinical outcomes with financial performance at integrated healthcare organizations. His clinical background and leadership experience in resource-challenged environments enable him to position organizations for sustainable success in today’s rapidly changing healthcare landscape. In his current role, Dr. Trenschel is responsible for overall health system strategy, physician and employee engagement and development of its clinically integrated network. Throughout his career, he had held various healthcare leadership roles at several highly regarded regional health systems, including executive vice president of the Harris Health System, senior vice president of medical group operations at Aurora Health Care, and chief medical officer and vice president of clinical operations at Florida Community Health Centers, among others. Prior to his roles as a healthcare industry executive, Dr. Trenschel served as a private practice physician from 1990-2000.

Dr. Trenchel is a Fellow for American College of Healthcare Executives (FACHE). He earned his Doctor of Osteopathic Medicine (D.O.) degree from Nova Southeastern University in Fort Lauderdale, Florida, and his master’s degree in public health from Florida International University in Miami, Florida.

What is Robert J. Trenschel's net worth?

The estimated net worth of Robert J. Trenschel is at least $203.00 as of September 9th, 2021. Mr. Trenschel owns 116 shares of Palisade Bio stock worth more than $203 as of December 22nd. This net worth approximation does not reflect any other investments that Mr. Trenschel may own. Learn More about Robert J. Trenschel's net worth.

How do I contact Robert J. Trenschel?

The corporate mailing address for Mr. Trenschel and other Palisade Bio executives is 20271 Goldenrod Lane, Germantown MD, 20876. Palisade Bio can also be reached via phone at (858) 704-4900 and via email at [email protected]. Learn More on Robert J. Trenschel's contact information.

Has Robert J. Trenschel been buying or selling shares of Palisade Bio?

Robert J. Trenschel has not been actively trading shares of Palisade Bio during the past quarter. Learn More on Robert J. Trenschel's trading history.

Who are Palisade Bio's active insiders?

Palisade Bio's insider roster includes John Finley (CFO), Thomas Hallam (CEO), and Robert Trenschel (Director). Learn More on Palisade Bio's active insiders.

Are insiders buying or selling shares of Palisade Bio?

During the last year, Palisade Bio insiders bought shares 3 times. They purchased a total of 2,666 shares worth more than $15,664.00. The most recent insider tranaction occured on May, 28th when Director Donald Allen Williams bought 1,000 shares worth more than $4,860.00. Insiders at Palisade Bio own 3.3% of the company. Learn More about insider trades at Palisade Bio.

Information on this page was last updated on 5/28/2024.

Robert J. Trenschel Insider Trading History at Palisade Bio

See Full Table

Robert J. Trenschel Buying and Selling Activity at Palisade Bio

This chart shows Robert J. Trenschel's buying and selling at Palisade Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Palisade Bio Company Overview

Palisade Bio logo
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
Read More

Today's Range

Now: $1.75
Low: $1.75
High: $1.86

50 Day Range

MA: $2.60
Low: $1.40
High: $3.91

2 Week Range

Now: $1.75
Low: $1.38
High: $22.35

Volume

120,416 shs

Average Volume

670,536 shs

Market Capitalization

$2.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39